Health Care & Life Sciences » Pharmaceuticals | Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Cumberland Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Total Stock Market Index Fund
194,545
1.25%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
192,500
1.24%
0
0.27%
12/31/2017
DFA US Micro Cap Portfolio
169,380
1.09%
0
0.01%
04/30/2018
DFA US Small Cap Portfolio
138,305
0.89%
0
0%
04/30/2018
DFA US Targeted Value Portfolio
100,209
0.64%
0
0.01%
04/30/2018
Vanguard Extended Market Index Fund
83,401
0.54%
0
0%
07/31/2018
Ariel Discovery Fund
75,119
0.48%
20,445
1.31%
06/30/2018
DFA Tax Managed US Targeted Value Portfolio
72,567
0.47%
1,601
0.01%
04/30/2018
DFA US Core Equity 2 Portfolio
40,261
0.26%
1,800
0%
04/30/2018
DFA Tax Managed US Small Cap Portfolio
39,913
0.26%
505
0.01%
04/30/2018

About Cumberland Pharmaceuticals

View Profile
Address
2525 West End Avenue
Nashville Tennessee 37203
United States
Employees -
Website http://www.cumberlandpharma.com
Updated 07/08/2019
Cumberland Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of brands for the hospital acute care, gastroenterology, and oncology. Its product brands include acetadote, caldolor, kristalose, hepatoren, omeclamox, vaprisol, boxaban, vasculan, ethyol, portaban, and totect. The company was founded by A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.